Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ZAFEMY safely and effectively. See full prescribing information for ZAFEMY. ZAFEMY® (norelgestromin and ethinyl estradiol transdermal system) Initial U.S. Approval: 2001
Medication labelWhy this: Advisory · dailymed-prescription
ZAFEMY® is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use: ZAFEMY may be less effective in preventing pregnancy in women who weigh 198 lbs (90 kg) or more. ZAFEMY is contraindicated for use in women with BMI ≥ 30 kg/m2 [see Contraindications (4), Warnings and Precautions (5.1) and Clinical Studies (14)].
- generic_name
- norelgestromin and ethinyl estradiol
- product_names
- Norelgestromin and Ethinyl Estradiol
- ndc
- 72162-2220, 65162-358, 72162-2220-2, 72162-2220-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en